78686-86-9

Basic information

• Product Name: 5-BROMO-2-CHLORO-3-PYRIDINECARBONYL CHLORIDE
• Synonyms: 5-BROMO-2-CHLORO-3-PYRIDINECARBONYL CHLORIDE;3-Pyridinecarbonyl chloride, 5-bromo-2-chloro-
• CAS NO: 78686-86-9
• Molecular Formula: C₆H₂BrCl₂NO
• Molecular Weight: 254.89618
• Mol File: 78686-86-9.mol
• Article Data: 15

Chemical Properties

• Boiling Point: 297.008 °C at 760 mmHg
• Flash Point: 133.426 °C
• Appearance: /
• Density: 1.858 g/cm³
• Vapor Pressure: 0.001mmHg at 25°C
• Refractive Index: 1.604
• CAS DataBase Reference: 5-BROMO-2-CHLORO-3-PYRIDINECARBONYL CHLORIDE(CAS DataBase Reference)
• NIST Chemistry Reference: 5-BROMO-2-CHLORO-3-PYRIDINECARBONYL CHLORIDE(78686-86-9)
• EPA Substance Registry System: 5-BROMO-2-CHLORO-3-PYRIDINECARBONYL CHLORIDE(78686-86-9)

Safety Data

• Hazardous Substances Data: 78686-86-9(Hazardous Substances Data)

Usage

General Description

5-Bromo-2-chloro-3-pyridinecarbonyl chloride, often referred to as 5-Bromo-2-chloronicotinoyl chloride, is a chemical compound with the formula C6H2BrCl2NO. As the name indicates, it has atoms of bromine, chlorine, nitrogen, oxygen, and carbon. It's a well-known halogenated carbonyl compound with various applications in chemical and pharmaceutical manufacturing. It plays a significant role as a derivatization or modification agent, typically used in the synthesis of a variety of pharmaceuticals. However, like many other such compounds, it needs to be handled with appropriate safety measures due to its reactivity and potential to cause harm on direct exposure.

InChI:InChI=1/C6H2BrCl2NO/c7-3-1-4(6(9)11)5(8)10-2-3/h1-2H

Upstream product

• 52833-94-0 2-amino-5-bromonicotinicacid 
• 104612-36-4 5-bromo-2-hydroxynicotinic acid 
• 609-71-2 2-hydroxy-3-carboxypyridine 
• 2942-59-8 2-chloronicotinic acid 
• 931105-54-3 Sodium 5-bromo-2-chloronicotinate 
• 32282-06-7 3-amino-2-(ethylamino)pyridine 
• 29241-65-4 5-bromo-2-chloronicotinic acid 

Downstream Products

• 211750-50-4 BIRK 122 
• 134698-42-3 5,11-dihydro-11-ethyl-8-bromo-6H-dipyrido[3,2-b:2',3'-e][1,4]diazepin-6-one 
• 162109-00-4 2-bromo-5-ethyl-10-methyl-5,10-dihydro-4,5,6,10-tetraazadibenzo[a,d]cyclohepten-11-one 
• 1289189-96-3 C₇H₇BrN₄ 
• 1188142-86-0 5-bromo-2-chloro-N,N-dimethylpyridine-3-carboxamide 
• 1189749-84-5 C₇H₆BrClN₂O 
• 952152-79-3 (S)-N-((3-(3,5-difluoro-4-(2-bromo-10-oxo-5,6,8,9-tetrahydro-10H-4,4b,7,9a-tetraazabenzo[a]azulen-7-yl)phenyl)-2-oxo-5-oxazolidinyl)methyl)acetamide 
• 1303983-13-2 C₂₆H₃₁FN₄O₅ 
• 1303541-16-3 C₂₆H₃₁FN₄O₅ 
• 1304084-66-9 C₂₆H₃₃N₃O₇S 

Relevant articles and documents

Synthesis of [14C]- and [13C6]-labeled potent HIV non-nucleoside reverse transcriptase inhibitor

5,11-Dihydro-11-ethyl-5-methyl-8-{2-{(1-oxido-4-quinolinyl)oxy}ethyl} -6H-dipyrido[3,2-b:2′,3′-e][1,4]diazepin-6-one, (1), labeled with carbon-14 in the quinoline-benzene ring, in one of the pyridine rings of the dipyridodiazepinone tricyclic moiety, and in the side chain, was prepared in three different syntheses with specific activities ranging from 44 to 47 mCi/mmol (1.63-1.75 GBq/mmol). In the first synthesis, 5,11-dihydro-11-ethyl-8- (2-hydroxyethyl)-5-methyl-6H-dipyrido[3,2-b:2′,3′-e][1,4] diazepin-6-one (2) was coupled to 4-hydroxyquinoline, [benzene- 14C(U)]-, using Mitsunobu's reaction conditions, followed by the oxidation of the quinoline nitrogen with 3-chloroperoxybenzoic acid to give ([14C]-(1a)) in 43% radiochemical yield. Second, 3-amino-2- chloropyridine, [2,6-14C]-, was used to prepare 8-bromo-5,11-dihydro- 11-ethyl-5-methyl-6H-dipyrido[3,2-b:2′,3′-e][1,4]diazepin-6-one (8), and then Stille coupled to allyl(tributyl)tin followed by ozonolysis of the terminal double bond and in situ reduction of the resulting aldehyde to alcohol (10). Mitsunobu etherification and oxidation as seen before gave ([ 14C]-(1b)) in eight steps and in 11% radiochemical yield. Finally, carbon-14 potassium cyanide was used to prepare isopropyl cyanoacetate (12), which was used to transform bromide (8) to labeled aryl acetic acid (13) under palladium catalysis. Trihydroborane reduction of the acid gave alcohol (14) labeled in the side chain, which was used as described above to prepare ([ 14C]-(1c)) in 4.3% radiochemical yield. The radiochemical purities of these compounds were determined by radio-HPLC and radio-TLC to be more than 98%. To prepare [13C6]-(1), [13C 6]-4-hydroxyquinoline was prepared from [13C 6]-aniline and then coupled to (2) and oxidized as seen before. Copyright

MITOCHONDRIAL ALDEHYDE DEHYDROGENASE 2 (ALDH2) BINDING POLYCYCLIC AMIDES AND THEIR USE FOR THE TREATMENT OF CANCER

The present invention provides compounds of formula I that bind to mitochondrial aldehyde dehydrogenase-2 (ALDH2), and methods of using said compounds to treat patients with i.a. cancer, Fanconi anemia and alcohol-related disorders. [Formula should be ins

HETEROCYCLIC COMPOUNDS AS INHIBITORS OF FATTY ACID BIOSYSNTHESIS FOR BACTERIAL INFECTIONS

The present invention relates to novel heterocyclic compounds which specifically inhibit bacterial FabI and can be used for the treatment of Staphylococcal infections.